StoneX Group’s Editas Medicine EDIT Stock Holding History

StoneX Group’s Portfolio EDIT Stock Details EDIT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-15,855	Closed	-$32.5K	–	999
2025 Q4	$32.5K	Buy	+15,855	New	+$45.8K	﹤0.01%	950

Other funds holding EDIT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

StoneX Group's EDIT Position: Q1 2026 in Review

StoneX Group sold out of Editas Medicine (EDIT) in Q1 2026, closing a stake of 15,855 shares — an estimated $32.5K sold.

StoneX Group first reported a position in EDIT in Q4 2025 and held it in 1 quarter. The position peaked at $32.5K in Q4 2025. 207 funds tracked by Wall St. Rank hold EDIT as of Q1 2026.

StoneX Group reported no remaining Editas Medicine position as of Q1 2026 after selling out during the quarter.
StoneX Group sold 15,855 Editas Medicine shares in Q1 2026, an estimated $32.5K.
StoneX Group first reported a position in Editas Medicine in Q4 2025 and held it in 1 quarter.
StoneX Group's Editas Medicine position peaked at $32.5K in Q4 2025.
207 funds tracked by Wall St. Rank held Editas Medicine as of Q1 2026.

Based on StoneX Group's 13F filing for Q1 2026, filed 14 May 2026.